SuperworthSchrodinger EPS SDGR
Diluted earnings per share by quarter and over the last twelve months, from 2019.
- Last 12 months, to Jun 30, 2026
- −$0.74
- Latest quarter, Q2 FY26
- $0.08
- Fiscal year 2025
- −$1.42
Schrodinger's earnings per share was −$0.74 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.08.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.42 | n/a |
| FY2024 | −$2.57 | −594% |
| FY2023 | $0.52 | n/a |
| FY2022 | −$2.09 | n/a |
| FY2021 | −$1.41 | n/a |
| FY2020 | −$0.50 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.08 | n/a | −$0.74 | |
| Q1 FY26 | −$0.81 | n/a | −$1.41 | |
| Q4 FY25 | $0.44 | n/a | −$1.42 | |
| Q3 FY25 | −$0.45 | n/a | −$2.41 | |
| Q2 FY25 | −$0.59 | n/a | −$2.48 | |
| Q1 FY25 | −$0.82 | n/a | −$2.63 | |
| Q4 FY24 | −$0.55 | n/a | −$2.57 | |
| Q3 FY24 | −$0.52 | n/a | −$2.45 | |
| Q2 FY24 | −$0.74 | −1333% | −$2.79 | |
| Q1 FY24 | −$0.76 | −143% | −$1.99 | |
| Q4 FY23 | −$0.43 | n/a | $0.52 | |
| Q3 FY23 | −$0.86 | n/a | $0.57 |
Against its peers
Companies in Drug Manufacturers - General nearest Schrodinger's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SDGRSchrodinger | −$0.74 | |
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| OMEROmeros | $1.52 | |
| NRIXNurix Therapeutics | $2.31 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| OGNOrganon | $0.77 | −71% a year |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Schrodinger
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.